Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Casper: A phase I, open-label, dose finding study of calaspargase pegol-mnkl (cala) in combination with cobimetinib (cobi) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
Authors
Charles D. Lopez
Oregon Health and Science University, Portland, OR;
Charles D. Lopez , Adel Kardosh , Emerson Yu-sheng Chen , Guillaume Joe Pegna , Shaun Goodyear , Erin Taber , Brindha Rajagopalan , Exodus Edmerson , Johnson Vo , Anna Jackson , Tasha Gingerich , Anne Fahlman , Diane Ventura , Preeyam Roy , Dove Keith , Gordon B. Mills , Jonathan Brody , Brett C. Sheppard , Rosalie C. Sears , Ze'ev Ronai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05034627
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS772)
DOI
10.1200/JCO.2023.41.4_suppl.TPS772
Abstract #
TPS772
Poster Bd #
Q8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update.
First Author: Chao Yin
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
First Author: Saranya Chumsri
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.
First Author: Anthony W. Tolcher
Poster
2023 ASCO Gastrointestinal Cancers Symposium
An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
First Author: Miaozhen Qiu